# Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

> **NCT02408549** · PHASE3 · COMPLETED · sponsor: **UCB BIOSCIENCES, Inc.** · enrollment: 239 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Lacosamide Tablet
- **DRUG:** Lacosamide Oral Solution

## Key facts

- **NCT ID:** NCT02408549
- **Lead sponsor:** UCB BIOSCIENCES, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-03
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2023-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02408549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02408549, "Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02408549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*